Vanda launches motion sickness drug after 40-year gap

Vanda Pharmaceuticals launched NEREUS (tradipitant) commercially in the U.S. after FDA approval on December 30, 2025, marking the first new prescription treatment for motion sickness in over 40 years. The company priced the drug at $85 per dose versus a $255 list price and said it could address a 65-78 million-person U.S. market, while analysts forecast 19% revenue growth in 2026 and EPS of $0.99 this year versus a $3.74 loss over the last 12 months. The news is positive for VNDA, though the article also includes mixed operational and policy items such as ongoing clinical development, a board appointment, and opposition to FDA budget legislation.

Analysis

VNDA is moving from a single-asset development story to a commercial optionality story, which changes the equity from a binary biotech to a launch-execution trade. The market is likely still underestimating how much value can be created if NEREUS becomes a durable cash-flow contributor, because even modest penetration in a large, under-treated niche can re-rate the company faster than the sell-side’s current profitability model implies.

The second-order upside is not just motion sickness demand; it is platform leverage. If the launch validates self-pay pricing and direct-to-consumer acquisition, management gets a repeatable commercialization playbook for the GLP-1 nausea program and other label expansions, which could matter more than this indication alone. That said, the biggest risk is that the initial launch mix looks good on paper but scales poorly: high list price, prescription friction, reimbursement ambiguity, and demand softness once novelty fades can quickly compress the market’s willingness to capitalize 2026 earnings.

Near term, the catalyst stack is dense: first post-launch ordering data, upcoming earnings, and any commentary on early refill rates, website conversion, or pharmacy uptake. Over the next few months, the stock should trade less on approval and more on whether revenue ramps faster than operating expense leverage. If management sounds promotional but does not quantify traction, the move can reverse sharply because the current setup prices in a credible path to profitability already.

Consensus may be too focused on the headline "first in 40 years" and not enough on execution risk and indication breadth. The bullish case is real, but the risk/reward is no longer asymmetric on approval alone; the stock needs evidence that NEREUS is not just a one-time launch but the opening of a broader CNS/GI franchise. If GLP-1 nausea development shows any credible early signal, the valuation ceiling could move materially higher, but absent that, the trade becomes a launch-decay story rather than a platform story.

Key Decisions for Investors

• Go long VNDA into earnings only if the position is sized as a catalyst trade, not a structural hold; target a 4-8 week window with tight risk control around management commentary on initial sell-through and DTC conversion.
• Buy VNDA call spreads for the next 1-2 earnings cycles to express upside from launch execution while capping premium burn if adoption is slower than expected; risk/reward improves if implied volatility remains elevated but not extreme.
• If already long VNDA, trim into strength after the first post-launch pop and re-add only on evidence of monthly prescription momentum or explicit guidance raising 2026 revenue expectations.
• Pair trade: long VNDA / short a basket of slower-growth biotech commercializers with richer valuations, expressing the view that launch execution can re-rate VNDA faster than peers over the next 1-3 months.
• Watch for a reversal trigger: if management fails to show measurable traction by the next quarterly print, consider shorting against strength or buying puts, since the current valuation already bakes in a meaningful portion of the profitability inflection.